Management of hepatic epithelioid haemangio-endothelioma in children: what option? by Sharif, K et al.
Management of hepatic epithelioid haemangio-endothelioma in
children: what option?
K Sharif
1, M English
1, P Ramani
2, D Alberti
3, J-B Otte
4, P McKiernan
5, S Gosseye
5, M Jenney
6 and
J de Ville de Goyet*,1
1Liver Unit and Department of Paediatric Oncology, Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH, UK;
2Department of
Pathology, Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH, UK;
3Liver Transplant Centre, Ospedali Riuniti, Largo Barozzi 1,
24100 Bergamo, Italy;
4Department of Paediatric Surgery, St Luc University Clinics Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium;
5Department of Pathology, St Luc University Clinics Brussels, Avenue Hippocrate 10, B-1200 Brussels, Belgium;
6Department of Paediatric Haemato-
Oncology, Llandough Hospital, Penlan Road, Llandough, Penarth, Vale of Glamorgan CF64 2XX, UK
Hepatic epithelioid haemangio-endothelioma (HEHE) is an endothelium-derived tumour of low-to-medium grade malignancy. It is
predominantly seen in adults and is unresponsive to chemotherapy. Liver transplantation is an accepted indication when the tumour is
unresectable. Hepatic epithelioid haemangio-endothelioma is very rare in children and results after transplantation are not reported.
The aim of this study is to review the experience of three European centres in the management of HEHE in children. A retrospective
review of all paediatric patients with HEHE managed in three European centres is presented. Five children were identified. Four had
unresectable tumours. The first had successful resection followed by chemotherapy and is alive, without disease 3 years after
diagnosis. One child died of sepsis and one of tumour recurrence in the graft and lungs 2 and 5 months, respectively, after transplant.
Two children who had progressive disease with ifosfamide-based chemotherapy have had a reduction in clinical symptoms and
stabilisation of disease up to 18 and 24 months after the use of platinum-based chemotherapy. HEHE seems more aggressive in
children than reported in adults and the curative role of transplantation must be questioned. Ifosfamide-based chemotherapy was not
effective. Further studies are necessary to confirm if HEHE progression in children may be influenced by platinum-based
chemotherapy.
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Hepatic epithelioid haemangio-endothelioma (HEHE) is a rare
tumour of vascular origin. Hepatic epithelioid haemangio-en-
dothelioma is a tumour of low-to-intermediate grade malignancy
and is distinct from the benign tumour ‘infantile haemangio-
endothelioma’ and the malignant tumour ‘angiosarcoma’.
Although the usual clinical course is characterised by both a very
slow progression and a malignant behaviour with local recurrence
and distant metastasis, its natural behaviour has also been
described as unpredictable (Dietze et al, 1989; Makhlouf et al,
1999). Prolonged survival without treatment (La ¨uffer et al, 1996;
Makhlouf et al, 1999; Uchimura et al, 2001) and even spontaneous
clearance has been seen, while in others the tumour has progressed
rapidly.
In the absence of effective chemotherapy strategies, tumour
resection is the only management option. Many cases present at
diagnosis with multifocal hepatic disease or large, widespread
tumours and conventional liver surgery is not possible. Since
HEHE progression is usually very slow, liver transplantation has
been proposed as a reasonable option in these cases (Scoazec et al,
1988; Madariaga et al, 1995). The 5-year actuarial survival
following liver transplantation for HEHE in adults is as high as
71% (disease-free survival¼60%) (Madariaga et al, 1995).
Most reports have been in adults and a female predominance
has been seen. In children, HEHE is extremely rare and manage-
ment is usually as for adults; however, very little information is
available in literature about the disease characteristics and
outcome in paediatric age range. For the purpose of this
retrospective review and report, a small series of children with
HEHE was collected from four European centres.
PATIENTS AND METHODS
Patients were collected from three European paediatric liver units
(St Luc University Clinics Brussels, Belgium; Transplant Unit,
Bergamo, Italy; and Liver Unit, Birmingham Children’s Hospital,
Birmingham, UK) and the Paediatric Haematology Oncology Unit,
Llandough Hospital, Wales, UK. All children (o16 years) with
histologically proven HEHE (typical histologic findings, Factor
VIII-related-Ag positive cells) were included for this retrospective
study. Details regarding demographic characteristics, mode of
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lpresentation, results of investigations, chemotherapy regimen,
type of interventions and the outcome were recorded.
RESULTS
Five children (four female) with a median age of 10.9 years (range
1.35–12.9 years) were identified from the participating centres.
Demographic details are shown in Table 1. Two children presented
with Budd Chiari syndrome and one with a rapidly growing
abdominal mass, and two had only vague upper abdominal pain.
Liver function tests and serum alpha feto-protein levels were
within the normal range for all cases at presentation. CT scan of
abdomen showed a large mass in the centre of the liver in one
patient (case 1), while in all the others multiple nodules involving
both liver lobes were seen. One child had lung metastases at
presentation (CT scan). The diagnosis was confirmed by liver
biopsy and positive immunohistochemistry of tumour cells for
factor VIII-related antigen.
The management strategies and outcome are summarised in
Table 2. Tumour resection was possible in only one patient; she
had a huge centrohepatic tumour and, in order to achieve
successful surgical resection, a total hepatectomy had to be done,
followed by an ex vivo extended hepatectomy and by auto-
transplant of the healthy residual liver segment. Macroscopically, a
radical resection was achieved, but there was evidence of
microscopic invasion in the residual liver. She underwent
chemotherapy (Table 2) after surgery and, interestingly, she is
currently alive and disease free, 3 years after surgery (28 months
after cessation of chemotherapy, 8 years of age).
Two children underwent liver transplantation. Both presented
with unresectable liver mass causing Budd–Chiari-like syndrome,
and were proposed for liver transplantation as primary manage-
ment. One of the two died 2 months after transplantation, from
respiratory failure due to lung fibrosis secondary to cytomegalo-
virus infection. The other child developed lung metastases and
recurrence of tumour in the graft 3 months after transplant; she
then received chemotherapy (one course) with no effect on tumour
and died (5 months after transplant).
The two most recent patients were started on chemotherapy
after the diagnosis. They presented with a few-month story of
abdominal pain and weight loss, and a widespread liver tumour
was found and, in the second case (case 5), lung metastases. In
both cases, no response was seen during chemotherapy (case 4-A
and 5-A in Table 3), with a slight increase of tumour masses and
development of lung metastases in case 4. Both were then switched
to a different chemotherapy regimen (4-B and 5-B in Table 3).
Further imaging (CT scan) showed, in case 4, a slight reduction of
the liver tumour mass and absence of progression of lung
metastases; this was associated with clinical improvement and
clearance of abdominal tenderness. A repeat surgical liver biopsy
was done at the end of chemotherapy where active HEHE was still
Table 1 Demographic features
Case no. Age at presentation (years) Sex Mode of presentation Primary management
1 4.4 Female Abdominal mass Resection
2 13 Female Budd Chiari syndrome Liver transplantation
3 1.3 Female Budd Chiari and intractable ascites Liver transplantation
4 12 Female Abdominal pain Chemotherapy
5 10 Male Abdominal Pain Chemotherapy
Table 2 Management strategy and outcome
Case no. Primary management Secondary management Outcome
1 Tumour resection (ex situ) Elective post-resection chemotherapy
a Alive and disease free, 3 years after diagnosis
2 Total hepatectomy (transplant) CMV pneumonia, death 2 months after transplant
3 Total hepatectomy (transplant) Recurrence at 3 months-chemotherapy
a Recurrence, death 5 months after transplant
4 Chemotherapy (A)
a Rescue chemotherapy (B)
a Alive, stable disease, 2 years after diagnosis
5 Chemotherapy (A)
a Rescue chemotherapy (B)
a Alive, stable disease, 18 months after diagnosis
aChemotherapy regimens: see Table 3.
Table 3 Chemotherapy and outcome
Case no. Treatment (see details
*) Response to treatment
1 SIOP MMT 952 protocol Unable to assess response (microscopic residues), no clinical recurrence after cessation of chemotherapy
2 No chemotherapy Refractory disease and death
3 SIOP MMT 952 protocol No response
4 A SIOP MMT 953 B protocol Developed pulmonary metastasis during treatment (7 weeks)-rescue chemotherapy (B)
B SIOPEL 3 High Risk Stable disease after 4 cycles of treatment
5 A SIOP MMT 952 protocol Progressive disease after 2 courses-rescue chemotherapy (B)
B Carboplatin, etoposide Stable disease after six cycles of treatment
*SIOP MMT 952 protocol: vincristine 1.5mgm
 2 (weeks 1, 2, 3, 4, 5, 6, 7, 10, 13, 16, 19, 22 and 25); actinomycin D 1.5 mgm
 2 (weeks 1, 4, 7, 10, 13, 16, 19, 22 and 25);
ifosfamide 6gm
 2 – over 2 days (weeks 1, 4, 7, 10, 13, 16, 19, 22 and 25). *SIOP MMT 953 B protocol: vincristine 1.5mgm
 2 (weeks 1, 2, 3, 4, 5, 6, 7, 10, 13, 16, 19, 22 and 25);
actinomycin D 1.5mgm
 2 (weeks 1, 10 and 19); ifosfamide 9gm
 2 over 3 days (weeks 1, 7, 10, 16, 19 and 25); carboplatin 500mgm
 2 (weeks 4, 10 and 22); epirubicin
150mgm
 2 (weeks 4, 10 and 22); etoposide 150mgm
 2 over 3 days, (weeks 7, 16 and 25). *SIOPEL 3 high risk (protocol for hepatoblastoma): cisplatin 80mgm
 2 (days 1, 29,
57 and 85); carboplatin 500mgm
 2 (days 15, 43 and 71); doxorubicin 60mgm
 2 over 48h (days 15, 43 and 71). *Carboplatin, etoposide: carboplatin 600–800mgm
 2 per
course; etoposide 150mgm
 2 (days 1, 2 and 3 each course).
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well and without evidence of further disease progression. The
other child (case 5) had lung metastases at diagnosis that grow
during the initial chemotherapy; however, there was a reduction of
primary tumour size and no further progression of lung nodes
after chemotherapy had been changed (Table 3). The latter child is
well 16 months after diagnosis and his clinical symptoms have
regressed, but he has now moderate portal hypertension. The
tumour sites did not progress further, but he has been off
chemotherapy for only few months and he waits further re-
evaluation of tumour extension (Figure 1).
DISCUSSION
Hepatic epithelioid haemangio-endothelioma is a rare and unique
neoplasm of vascular origin, now considered a entity distinct from
usual haemangioma, infantile type of haemangio-endothelioma or
angiosarcoma (Ishak et al, 1984). Hepatic epithelioid haemangio-
endothelioma is generally described as a low-to-intermediate grade
malignant tumour (Ishak et al, 1984; Dietze et al, 1989; La ¨uffer
et al, 1996). It seems to be more frequent among young women
and the role of prolonged use of oral contraceptives has been
questioned (Makhlouf et al, 1999). It may be found incidentally but
around half of patients present with upper abdominal pain or
discomfort; rare presentations include jaundice, Budd–Chiari-like
syndrome or liver failure. Radiological features (CT or MRI) vary:
HEHE may present as a large liver mass (one case in this series),
but more often the tumour is diffuse with multiple peripheral
hepatic lesions with capsular retraction, peripheral contrast
enhancement and evidence of multiple calcifications (Van Beers
et al, 1992). The latter lesion type has been considered as a
progression, with time, of the former unifocal mass type. Diagnosis
can only be confirmed with histology (preferably a surgical biopsy)
and the finding of factor VIII-related-Ag positive cells on
immunohistochemical staining (Ishak et al, 1984; Uchimura et al,
2001).
Since Ishak et al reported first series of 32 cases in 1984, fewer
than 200 cases have been reported in literature. Makhlouf et al
(1999) reported the largest clinicopathologic study of 137 cases of
various age ranging from 12 to 86 years (including 32 reported by
Ishak et al, 1984). Out of this series, only seven cases were less than
20 years of age, and their treatment and outcome was not analysed
separately. Overall, there is a lack of information in literature
about HEHE in children and it is not known whether the behaviour
of HEHE in children is similar to that of adults.
In adults, HEHE is characterised by a very slow progression
(Demetris et al, 1997), and possible prolonged survival without
treatment (Makhlouf et al, 1999). Only a few cases can be managed
by partial liver resection, since the tumour tends to be widespread
within liver at the time of diagnosis. In that setting, liver
transplantation has been proposed with reasonable success since
the disease usually progresses extremely slowly, even extra-hepatic
disease has not been considered a contraindication (Scoazec et al,
1988; Kelleher et al, 1989; Madariaga et al, 1995; Ben-Haim et al,
1999; O’Grady, 2000). Madariaga et al (1995) reported a 71% 5-year
actuarial patients survival (60% actuarial disease-free survival at 5
years post-OLT). Surprisingly, prolonged disease-free survival has
been seen in transplanted patients who had disseminated disease,
when other patients transplanted with disease confined to the liver
developed rapid recurrence and metastasis (Demetris et al, 1997;
Ben-Haim et al, 1999).
Report of children after transplantation is anecdotical; Taege
et al (1999) reported one child who had a slowly progressing HEHE
despite chemotherapy (no extra-hepatic disease) and who
benefited from transplantation. He is alive and well free of disease
3 years after transplantation (Dr Melker, Hannover – personal
communication). In the current series, one child who survived the
post-transplant period developed rapid disease recurrence and
died; the latter pattern of disease progression is more similar to
that reported after transplantation for angiosarcoma. Interestingly,
the child reported by Taege et al (1999) was older and did receive
pre-operative chemotherapy, while the child in this series was
younger and did not receive pre-operative chemotherapy.
It is usually considered that chemotherapy is not effective
against HEHE in adults, and the few paediatric reports are in line
with this consideration. Dietze et al (1989) described a 12-year-old
girl who died within 1.5 months after starting chemotherapy. In
their case report, Taege et al (1999) considered that chemotherapy
was unsuccessful and decided to propose transplantation. How-
ever, our observations suggest that some response may be
observed and this would support developing further management
protocols. Although the follow-up in our series is short, one child
with a very rapidly growing HEHE, who had resection followed by
chemotherapy, is well and free of recurrence 3 years after
operation, despite microscopic residual disease after surgery.
Also, tumour progression seemed to slow down and liver masses
decreased in size after chemotherapy in two patients with extensive
liver disease and lung metastases.
Overall, this small series and the review of literature suggest that
HEHE in the paediatric population, particularly in very young
children, does not appear to behave as favourably as HEHE seen in
adults. On the contrary, it is often a relatively rapidly growing
tumour with a more malignant behaviour. If resection of the
Figure 1 Hepatic epitheloid haemangio-endothelioma in a 10-year-old
child. CT scan aspect before and after chemotherapy (carboplatin,
etoposide), showing some response to chemotherapy that was associated
with resolution of clinical symptoms.
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and children. However, if this is not possible, transplantation may
not be the best management option for children and chemotherapy
as pre-operative treatment or as the only treatment should be
considered. It appears both from this report and that of Dietze et al
(1989) that ifosfamide-based chemotherapy is not effective.
However, three out of four patients in our series who had
chemotherapy did improve and remain alive, including two who
were deteriorating rapidly prior to treatment. Chemotherapy with
carboplatin, cisplatin and adriamycin stabilised the disease in one
patient and carboplatin and etoposide brought about a partial
response followed by stabilised disease in another. Moreover, Pinet
et al (1999) have reported a complete response after carboplatin
and etoposide in an aggressive form of pleural epithelioid
haemangio-endothelioma. Overall, we suggest that carboplatin
and etoposide be considered for further study in paediatric HEHE.
One case report suggests interferon alpha may also be effective
(Kayler et al, 2002).
In conclusion, HEHE in children may have a more malignant
behaviour compared to that reported in adults and results of
surgery alone are not good. Liver transplantation for cases with
unresectable disease, as done in adults, may therefore not be
appropriate for managing children with HEHE. We believe that
new chemotherapy or alternative drug regimens should be
explored as primary management of nonresectable HEHE
tumours. It is possible that more effective chemotherapy may, in
turn, increase the chance of offering surgical management as a
complementary treatment and with improved outcome; in that
context also, the place of transplantation for children with HEHE
may be reconsidered in the future.
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